Krish Ramadurai is a Partner at AIX Ventures, an AI-focused, seed-stage venture capital firm backing top startups and practitioners in artificial intelligence, healthcare, and life sciences.
At AIX, Krish leads technical diligence, deal sourcing, and portfolio operations, having sourced and managed more than 45 early- and growth-stage investments driving over $20 billion in cumulative portfolio value. His track record includes successful exits and unicorns such as Volumetric Biotechnologies, PathologyWatch, Trials.AI, and more.
A Harvard- and Oxford-trained biomolecular engineer, Krish has supported more than 25 pioneering scientific breakthroughs—from the world’s first AI-designed drug to enter human trials to the first commercial rideshare satellite launched into space. He has served as a chairman and board member for leading AI and life sciences companies, lectured at Harvard, and published research spanning applied engineering, AI, and medicine.
%20(1).png)
.png)